For discussion
On 17 June 2014

Legislative Council Panel on Commerce and Industry

Research and Development of Chinese Medicines

PURPOSE

This paper updates Members on the progress of effort made in promoting research and development (R&D) of Chinese medicines (CM).

BACKGROUND

2. The Government has been attaching great importance to the development of Chinese medicine in Hong Kong and striving to promote the sustainable development of the local CM industry. To facilitate collection of views from stakeholders and better coordinate effort in promoting R&D and testing of CM, the Committee on Research and Development of Chinese Medicines (the Committee) was established in December 2011. The Committee is chaired by the Commissioner for Innovation and Technology
and comprises representatives from the Government, industry, academic and research sectors. The current membership and terms of reference of the Committee are at *Annex 1*.

3. The Committee has adopted the following broad directions to promote the development of the CM sector in Hong Kong -

   (A) strengthening the support for R&D of CM;

   (B) promoting testing and certification of CM;

   (C) facilitating collaboration among stakeholders;

   (D) understanding and supporting industry needs; and

   (E) promoting the work of the Committee to the industry and the community.

More details are provided in the paragraphs below.

(A) **STRENGTHENING THE SUPPORT FOR R&D OF CM**

**Support provided via ITF**
4. The Government provides support to applied research of CM mainly through the Innovation and Technology Fund (ITF). Since 2012, a special theme on R&D of CM has been included in the invitation of proposals under the Innovation and Technology Support Programme (ITSP). In the past 3 years, more than 20 CM-related R&D projects were approved under ITF with funding of some $45 million. These research projects cover R&D of new CM, technologies related to CM testing and quality control (QC), pre-clinical and clinical evaluation of CM, study on CM standards, as well as integrative Chinese and Western medicines. For example, ITF supported an ITSP platform project conducted by Hong Kong Baptist University in collaboration with The Chinese University of Hong Kong (CUHK), The Hong Kong Polytechnic University and The Hong Kong University of Science and Technology (HKUST) to study local QC standards for 16 decoction pieces derived from 16 Chinese materia medica (CMM) included in the Hong Kong Chinese Materia Medica Standards (HKCMMS). Results of this project would be useful reference for the testing and certification of the corresponding decoction pieces and basis for further research in this area. Another example is a new CM R&D project carried out by a HKUST research team to develop agents derived from Chinese medicinal herbs for the treatment of several important neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and multiple sclerosis.

\footnote{Under the management and coordination of Department of Health, Hong Kong has been developing the HKCMMS. With the release of the “Hong Kong Chinese Materia Medica Standards (HKCMMS) Volume VI” in December 2013, six editions of HKCMMS covering standards for a total of 200 Chinese Materia Medica have been published.}
Clinical trials

5. To provide stronger support to downstream R&D and commercialisation activities, the scope of ITF funding has been expanded to cover more downstream activities, including testing to enable compliance with industrial standards, as well as clinical trials. This improvement can facilitate CM-related research projects to fulfill certain regulatory or technical requirements, hence increasing the commercialisation potentials of the project deliverables.

6. To encourage local researchers and the industry to utilise ITF funding support for R&D of CM, workshops and sharing sessions would be organised in the near future to introduce the recent ITF enhancement and the assessment framework of ITF applications.

(B) PROMOTING TESTING AND CERTIFICATION OF CM

7. The Government set up the Hong Kong Council for Testing and Certification (HKCTC) in 2009 to promote the testing and certification industry in Hong Kong. CM is one of the specific trades considered by HKCTC to have good potentials for generating demand for using testing and certification services.

8. In the past few years, HKCTC has made various efforts to
promote the development of testing and certification of CM. Examples are the introduction of inter-laboratory comparison programmes and new accreditation services for CM testing laboratories based on HKCMMS.

**Inter-laboratory comparison programmes**

9. On the front of providing inter-laboratory comparison programmes, the CM Panel of HKCTC organised the first inter-laboratory comparison exercise on chemical testing for CM based on HKCMMS in 2012 to enhance the technical capability of testing laboratories in the testing of CM, with participation of 12 laboratories. Through this exercise, the laboratories can assess their technical capability in conducting CM testing by comparing testing results with other laboratories. The second inter-laboratory comparison exercise for testing laboratories, which aims to cover a total of 12 CMM, has just begun with the participation of 15 local testing laboratories.

**Accreditation of CM testing laboratories**

10. Furthermore, on the front of accreditation of CM testing laboratories, in view of the needs of the industry and the community at large, the Hong Kong Accreditation Service under the Innovation and Technology Commission (ITC) has launched new accreditation services to cover authentication and testing of CM based on HKCMMS since March 2011. As of March 2014, 12 laboratories have been accredited for testing heavy
metals, pesticide residues and microbial contents of CM. Since the first inter-laboratory comparison exercise on CM testing organised by HKCTC, 6 of these CM testing laboratories have also been accredited for authentication, quality testing, or safety testing of CMM according to the corresponding HKCMMS.

(C) FACILITATING COLLABORATION AMONG STAKEHOLDERS

Seminar on R&D of CM

11. Building on the success of the Seminar on Chinese medicines organised by the Committee in 2012, the Committee organised a 2-day “Seminar on Research and Development of Chinese Medicines – Present and Future” in conjunction with the Department of Health (DH), Hospital Authority (HA) and HKCTC again in September 2013 to facilitate collaboration among the Government, industry, academic and research sectors, and to encourage sharing of knowledge on R&D of CM.

12. More than 30 guest speakers were invited to speak in this seminar. In the first part, the Secretary for Food and Health, Dr Ko Wing-man, and the Deputy Director-General of the Department of Science and Technology of the State Administration of Traditional Chinese Medicine, Professor Huang Lu-qi, spoke on the “Development of Chinese medicine in Hong Kong” and “Research on the sustainability of CM
resources in the Mainland”, respectively. Other speakers gave keynote speeches on the latest R&D trends in Chinese medicine, commercialisation of CM R&D outcomes, Product Certification Scheme for CMM and intellectual property protection for CM. The theme of the second part was "Integrative Medicine" whereby experts and academics from the Mainland, Macau and Hong Kong shared their research findings and experience on integration and development of evidence-based Chinese and Western medicine in treating diseases such as rheumatoid arthritis, digestive diseases, neurodegenerative diseases, lung cancer, liver cancer, colorectal cancer and prostate cancer. The seminar programme is at Annex 2.

13. Over 500 participants from the Chinese medicine community attended the seminar, which has become one of the biggest events organised by Government in the field of R&D of CM. The Committee plans to organise a similar event this September and believes that it will continue to serve as an important platform for exchanging ideas and exploring collaboration opportunities.

(D) UNDERSTANDING AND SUPPORTING INDUSTRY NEEDS

14. To ensure the quality and safety of proprietary Chinese medicines (pCm) and to keep up with international trends of developing Good Manufacturing Practice (GMP) for medicines, it was announced in the 2010-11 Policy Address that a timetable for mandatory compliance with
GMP for manufacture of pCm would be worked out. While the Chinese Medicine Council of Hong Kong/DH have been actively engaging the industry and conducting consultations to gather views from the CM industry on the timetable and detailed proposal for implementation of mandatory GMP, the Committee and ITC have been studying the R&D and technical aspects of the subject and exploring ways of supporting the industry.

**CM GMP training**

15. The Committee noted that the lack of proper understanding of GMP can be one of the factors deterring many local CM manufacturers from setting up GMP production, and recommended Government to support relevant training activities to help local pCm manufacturers get prepared for the future implementation of mandatory GMP requirements. In this regard, the General Support Programme under ITF approved funding of about $2.1 million in June 2013 to support a one-year project conducted by the Hong Kong Institute of Biotechnology (HKIB) to provide basic GMP training to all the local manufacturers free of charge. This project includes a series of activities such as basic GMP training classes, GMP facility visits, surveys by questionnaires and on-site company interviews [Annex 3]. The CM manufacturers participating in such training activities are expected to be enriched with the basic knowledge, expert advice and financial considerations involved in the implementation of GMP. At the same time, the current situation of the CM manufacturing industry as well as the views and needs of local CM manufacturers on GMP implementation would be
studied.

16. To date, a total of 11 rounds of 2-day basic GMP training classes have been organised, with a total of 177 representatives from 101 local CM companies participated in this training. The final results of the project are expected to be available in the second half of 2014. Separately, with the kind assistance of HKIB and DH, ITC has produced a video for introducing the basic concept of pCm GMP and will share it with interested parties in the future.

CM GMP Contract Manufacturing and Technical Support

17. The Committee is also aware of the concerns of the industry for hardware support for GMP, especially for SMEs that lack the financial strength and expertise to support the building of GMP facilities and their subsequent operation. The Committee agreed that Government should explore the possibility of assisting the establishment of appropriate technical support and contract manufacturing services to support the local CM industry. In this connection, HKIB has submitted a proposal, “GMP Project Development and Technical Support Platform for Traditional Oral Solid Proprietary Chinese Medicines Products”, requesting ITF and The Hong Kong Jockey Club Charities Trust (HKJCCT) to provide funding support of $24.81 million and $9 million, respectively, for a three-year project in setting up a GMP product development and technical support platform for traditional oral solid pCm products. In brief terms, the
submission to HKJCCT is to seek funding support for the renovation cost (which is beyond the funding scope of ITF), whereas the ITF support will be used to cover the costs of manpower, equipment, as well as operation and promotion activities of this project.

18. Details of the project are as follows -
   (a) expanding HKIB’s existing pCm GMP production area from 2880ft\(^2\) to 8500ft\(^2\);
   (b) increasing the contract manufacturing capacity of the 2 existing pCm formulations by 30\% and 150\%, respectively;
   (c) establishing production lines for 2 new types of pCm solid formulations, which will enable HKIB to provide GMP contract manufacturing services for the 4 most common types of pCm solid formulations in Hong Kong after project completion;
   (d) establishing a turnkey solution on technical support and pCm GMP-complied contract manufacturing services for local pCm manufacturers and researchers; and
   (e) establishing a GMP training platform on pCm manufacturing to equip CM workers and students (such as providing internship opportunities for students studying relevant professional programmes at the Vocational Training Council) with the necessary skills and practical experience to support the upgrading and development of the local CM industry.

[N.B. The HKIB, located in the CUHK campus in Shatin, New Territories, is a Company Limited by Guarantee wholly controlled by the Council of]
CUHK. Over the years, HKIB, as a neutral and not-for-profit research institution, has conducted multiple projects to assist the local pharmaceutical industry to comply with mandatory GMP requirements. In 1997, with funding from the former Industry Support Fund (ISF) under the now defunct Industry Department, it established the Hong Kong Pharmaceutical Technology Centre to provide local western pharmaceuticals manufacturers with detailed information, consultancy and training programmes on means to comply with GMP guidelines. In 1998 and 2000, HKIB received funding from the former ISF and ITF, respectively, to establish pilot-scale CM manufacturing facilities for R&D purpose. HKIB subsequently obtained GMP certificates issued by the Therapeutic Goods Administration of Australia and the Chinese Medicines Board of Hong Kong in 2004 and 2005, respectively, and extended its GMP consulting services to CM manufacturers.]

19. Representatives of HKIB were invited to present this proposal to the Committee in December 2013. The Committee supported the proposal and unanimously agreed that HKIB was a suitable organisation to conduct such project and considered it timely and consistent with ITF’s objective in promoting R&D and industry upgrading, as well as the Government policy in supporting the development and modernisation of CM. The project outcome is expected to bring direct benefits and important support to the local CM industry, particularly SMEs, by facilitating them to manufacture high quality and safe pCm products, as well as strengthening their capability to meet the mandatory GMP requirements in future. In
addition, the Committee noted that supporting letters for this proposal have been collected by HKIB from various industry associations, e.g. The Chinese Manufacturers’ Association of Hong Kong, Federation of Hong Kong Industries, Hong Kong Chinese Prepared Medicine Traders Association, Modernized Chinese Medicine International Association, Hong Kong Chinese Patent Medicine Manufacturers’ Association.

20. We have been advised by HKJCCT that it has approved a funding support of $10.8 million (including $9 million requested by HKIB, and $1.8 million for inflation allowance and contingency reserve for the renovation work) to cover the renovation cost of this project on the condition that the project costs of manpower, equipment, as well as operation and promotion activities will be covered by ITF. Subject to Members’ support, we will commit a funding amount in the region of about $23 million from ITF to support this project. [N.B. As the requested funding support from ITF for this project is within the delegated authority of ITC to approve individual projects not exceeding $30 million, approval by the Finance Committee of the Legislative Council is not required.]

(E) PROMOTING THE WORK OF THE COMMITTEE TO THE INDUSTRY AND THE COMMUNITY

Advertorial Series on CM
21. To keep up with the momentum of promoting the latest development of CM R&D in Hong Kong to the public, advertorials which included interviews of the Secretary for Food and Health, and representatives from DH, HA, local universities were published in major local newspapers last year. Some examples of these advertorials are enclosed at *Annex 4*.

**Publication of Booklet of the Radio Programme Series on CM**

22. The ITC has also collaborated with the Radio Television Hong Kong to produce a radio programme series on CM in 2012-13. The programme consists of twenty 30-minute episodes with expert guest speakers from Government, public bodies, local universities and research institutions. The programme content covered modernisation of CM, CM R&D activities conducted in local universities, the work of different CM-related organisations, and various CM topics that are of interest to the general public. For a wider reach out to the public, a booklet based on the excerpts of this Radio Programme Series has been published and more than 12,000 copies of this booklet have been distributed to interested parties through ITC, as well as with the help of the Chinese Medicine Department of HA, the secretariat of the Chinese Medicine Council of Hong Kong and CM trade associations *[Annex 5]*.
RELATED DEVELOPMENT

23. The Committee on Research and Development of Chinese Medicines and ITC have been rendering full support to the Chinese Medicine Development Committee (CMDC) chaired by the Secretary for Food and Health, and its Chinese Medicines Industry Subcommittee (CMISC) since their establishment in February 2013. The Commissioner and Deputy Commissioner for Innovation and Technology are ex-officio members of CMDC and CMISC, respectively. We will continue to collaborate with CMDC, and Food and Health Bureau/DH in promoting the overall development of CM in Hong Kong, especially in supporting R&D, testing and certification of CM and technology upgrading of the local CM industry.

ADVICE SOUGHT

24. Members’ views will be most welcome.

Innovation and Technology Commission
June 2014
COMMITTEE ON RESEARCH AND DEVELOPMENT OF CHINESE MEDICINES

Membership List

Chairperson
Commissioner for Innovation and Technology

Members (in alphabetical order)
Mr. AU Wai-hung, Anthony, BBS
Dr. CHAN Leung-cho
Mrs. CHENG CHO Chi-on, Mariana, BBS, JP
Dr. CHENG Heung-kwan, Celine
Mrs. CHIN Hang-yin, Alice
Prof. IP Yuk-yu, Nancy, MH
Prof. LAO Li-xing
Prof. LEUNG Ping-chung, SBS, JP
Mr. LI Ying-sang, Tommy, BBS, MH, JP
Prof. LIU Liang
Prof. LU Ai-ping
Ms. TANG Mui-fun, Karen
Mr. TSANG Chiu-hing
Mr. WONG Kong-hui, Kenlay, MH
Prof. WONG Ngar-kok, James, MH
Ms. WONG Suet-ying, Alice
Director of Health or representative
Representative of the Hospital Authority
Representative of the Hong Kong Council for Testing and Certification
Representative of the Hong Kong Science and Technology Parks Corporation
Representative of The Hong Kong Jockey Club

Terms of Reference

The terms of reference of Committee on Research and Development of Chinese Medicines are:

(a) To act as a platform to gauge views from various stakeholders, including Government, public bodies, industry and the academia on the research and development of Chinese medicines in Hong Kong;

(b) To formulate the broad direction in promoting research and development of Chinese medicines in Hong Kong, to identify key areas of work, monitor progress and recommend areas of improvement where necessary; and

(c) To facilitate sharing of research and development outcome and other collaboration among parties concerned to create synergy in research and development of Chinese medicines and to promote collaboration with organisations outside Hong Kong.
Seminar on
Research and Development
of Chinese Medicines
Present and Future
## Program

### 2013 年 9 月 5 日 (星期四) 5 September 2013 (Thursday)

<table>
<thead>
<tr>
<th>Start Time</th>
<th>Topics and Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am</td>
<td>Registration</td>
</tr>
<tr>
<td>9:30 am</td>
<td>Welcoming Remarks</td>
</tr>
</tbody>
</table>
|            | Miss WONG Wing-chen, Janet  
|            | Chairperson of Committee on Research and Development of Chinese Medicines; and Commissioner for Innovation and Technology, HKSAR Government |
|            | Dr CHAN Hon-yee, Constance  
|            | Director of Health, HKSAR Government |
|            | Dr CHEUNG Wai-lun, Allen  
|            | Director (Cluster Services), Hospital Authority |
| 9:40 am    | Group Photo with Guests and Speakers |
| 9:45 am    | The Development of Chinese Medicine in Hong Kong  
|            | Dr KO Wing-man  
|            | Secretary for Food and Health, HKSAR Government |
| 10:15 am   | Research on the Sustainability of Chinese Medicines Resources in China  
|            | Prof HUANG Lu-qi  
|            | Deputy Director General of the Department of Science and Technology, State Administration of Traditional Chinese Medicine |
| 10:45 am   | Tea Break |
| 11:05 am   | Latest R&D Trend in Chinese Medicine  
|            | Prof LAO Li-xing  
|            | Director, School of Chinese Medicine, The University of Hong Kong (HKU) |
| 11:35 am   | Commercialisation of R&D : Coartem*, Taking a TCM from Laboratory to Regulatory Approval  
|            | Dr Heiner GRUENINGER  
|            | Global Program Head for Tropical Medicines, Novartis |

主辦機構保留調動研討會題目，內容及講者的權利而不須预先通知。
The organiser reserves the right to alter the topic/content/speaker of the seminar programme without prior notice.
<table>
<thead>
<tr>
<th>Start Time</th>
<th>Topics and Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:05 pm</td>
<td>Product Certification Scheme for Chinese Materia Medica</td>
</tr>
<tr>
<td></td>
<td>Mr TSANG Kam-lam</td>
</tr>
<tr>
<td></td>
<td>General Manager, Environmental Management Division, Hong Kong Productivity Council</td>
</tr>
<tr>
<td>12:25 pm</td>
<td>Panel Discussion: Promoting the Development of Chinese Medicines</td>
</tr>
<tr>
<td></td>
<td>Dr PANG Wai-bing, Cecilia</td>
</tr>
<tr>
<td></td>
<td>Biotechnology Director, Innovation and Technology Commission, HKSAR Government</td>
</tr>
<tr>
<td></td>
<td>Dr Ronald LAM</td>
</tr>
<tr>
<td></td>
<td>Assistant Director (Traditional Chinese Medicine), Department of Health, HKSAR Government</td>
</tr>
<tr>
<td></td>
<td>Dr Lawrence LAI</td>
</tr>
<tr>
<td></td>
<td>Convener of the Panel on Promoting Testing and Certification Services in Chinese Medicines Trade of the Hong Kong Council for Testing and Certification</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Intellectual Property Protection for Chinese Medicines</td>
</tr>
<tr>
<td></td>
<td>Mr Peter CHEUNG</td>
</tr>
<tr>
<td></td>
<td>Director of Intellectual Property, HKSAR Government</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Integrative Medicine in the Mainland</td>
</tr>
<tr>
<td></td>
<td>Prof TANG Xu-dong</td>
</tr>
<tr>
<td></td>
<td>Principal Investigator and Director of Xi Yuan Hospital, China Academy of Chinese Medical Sciences</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Disease Area: Rheumatoid Arthritis</td>
</tr>
<tr>
<td></td>
<td>Prof LAU Chak-sing</td>
</tr>
<tr>
<td></td>
<td>Chair Professor of Rheumatology and Clinical Immunology, Department of Medicine, The University of Hong Kong</td>
</tr>
<tr>
<td></td>
<td>Chair Professor LIU Liang</td>
</tr>
<tr>
<td></td>
<td>Rector of Macau University of Science and Technology</td>
</tr>
</tbody>
</table>
| 開始時間  
Start Time | 主題及講者  
Topics and Speakers |
|-----------|-----------------|
| 4:10 pm  | 小休及茶點  
Tea Break |
| 4:30 pm  | 疾病範疇：消化系統疾病 |
|          | Disease Area : Digestive Diseases |
|          | 香港中文大學中西醫結合醫學研究所主任  
Prof WU Che-yuen, Justin  
Director of Institute of Integrative Medicine,  
The Chinese University of Hong Kong (CUHK) |
|          | 香港浸會大學協理副校長兼中醫藥學院臨床部主任  
Prof BIAN Zhao-xiang  
Associate Vice-President; and Director of Clinical Division of  
School of Chinese Medicine, Hong Kong Baptist University (HKBU) |
| 5:10 pm  | 疾病範疇：神經退化性疾病 |
|          | Disease Area : Neurodegenerative Diseases |
|          | 香港中文大學內科及治療學系教授  
Prof KWOK Chi-yui, Timothy  
Professor, Department of Medicine and Therapeutics, CUHK |
|          | 香港浸會大學中醫藥學院中醫課程主任、教學部副教授  
Dr LI Min  
Programme Director and Associate Professor, Teaching  
Division, School of Chinese Medicine, HKBU |
| 5:50 pm  | 首日程序完結  
End of Programme on First Day |

主辦機構保留調動研討會題目，內容及講者的權利而不須預先通知。
The organiser reserves the right to alter the topic/content/speaker of the seminar programme without prior notice.
<table>
<thead>
<tr>
<th>Start Time</th>
<th>Topics and Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 am</td>
<td>Registration</td>
</tr>
</tbody>
</table>
| 9:00 am   | Study on Advanced Non-small Cell Lung Cancer Treatment Scheme of Western Medicine Combined with Traditional Chinese Medicine  
            | Prof LIU Jia-xiang  
            | Chief, Department of Oncology, Longhua Hospital of Shanghai University of Traditional Chinese Medicine |
| 9:30 am   | Integrated Traditional Chinese and Western Medicine on Non-Small Cell Lung Cancer Treatment  
            | Mr XU Kai  
            | Senior Teaching Consultant, School of Chinese Medicine, HKU |
| 10:00 am  | Traditional Chinese Medicine on Liver Cancer Treatment under Treatment Aiming at Its Root Causes  
            | Prof LU Ai-ping  
            | Dean, School of Chinese Medicine, HKBU |
| 10:30 am  | Identification and Characterization of Cancer Stem Cells in Liver Cancer  
            | Prof GUAN Xin-yuan  
            | Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, HKU |
| 11:00 am  | Tea Break           |
| 11:15 am  | Development and Prospect of Integrated Chinese and Western Medicine in Colorectal Cancer  
            | Prof YANG Yu-fei  
<pre><code>        | Chief, Department of Oncology, Xi Yuan Hospital of China Academy of Chinese Medical Sciences |
</code></pre>
<table>
<thead>
<tr>
<th>Start Time</th>
<th>Topics and Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45 am</td>
<td>Evolution of Evidence-Based Western Medicine Treatment in Colorectal Cancer: Prospect for Integrative Medicine&lt;br&gt;Dr HUI Pun, Edwin&lt;br&gt;Director, Comprehensive Cancer Trials Unit, Department of Clinical Oncology, CUHK</td>
</tr>
<tr>
<td>12:15 pm</td>
<td>Chinese Medicine for Side Effects from Chemotherapy for Colorectal Cancer&lt;br&gt;Prof BIAN Zhao-xiang&lt;br&gt;Associate Vice-President; and Director of Clinical Division of School of Chinese Medicine, HKBU</td>
</tr>
<tr>
<td>12:45 pm</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>1:15 pm</td>
<td>Development of Evidence-Based Chinese Medicine and Western Medicine in Prostate Cancer&lt;br&gt;Dr CHEN Jian-ping&lt;br&gt;Associate Professor, School of Chinese Medicine, HKU</td>
</tr>
<tr>
<td>2:15 pm</td>
<td>The Strategies and Practices of Chinese Medicine in the Treatment of Prostate Cancer&lt;br&gt;Prof CHEN Zhi-qiang&lt;br&gt;Vice President of the Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, also known as Guangdong Provincial Hospital of Traditional Chinese Medicine</td>
</tr>
<tr>
<td>2:45 pm</td>
<td>Herbal Medicine as an Alternative Therapeutic Strategy for Prostate Cancer: Possibility Based on Evidences from Basic Research&lt;br&gt;Prof CHAN Leung, Franky&lt;br&gt;Professor and Chief of the Cancer &amp; Inflammation Program, School of Biomedical Sciences, CUHK</td>
</tr>
<tr>
<td>3:15 pm</td>
<td>Phytotherapy for Carcinoma of Prostate&lt;br&gt;Dr YIP Wai-chun, Andrew&lt;br&gt;Consultant, Department of Surgery, Kwong Wah Hospital; Specialist in Urology</td>
</tr>
<tr>
<td>3:45 pm</td>
<td>Tea Break</td>
</tr>
</tbody>
</table>

The organiser reserves the right to alter the topic/content/speaker of the seminar programme without prior notice.
### 程序 Programme

<table>
<thead>
<tr>
<th>開始時間</th>
<th>主題及講者</th>
<th>Topics and Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>4:00 pm</strong></td>
<td>Visioning the Future - Insights from Current Chinese Medicine Models and Experts’ Sharing Session</td>
<td></td>
</tr>
<tr>
<td><strong>4:30 pm</strong></td>
<td>Clinical Application and Prospect of Traditional Chinese Medicine in Oncology</td>
<td></td>
</tr>
<tr>
<td><strong>5:00 pm</strong></td>
<td>The Role of Western Medicine in Integrative Cancer Therapies</td>
<td></td>
</tr>
<tr>
<td><strong>5:15 pm</strong></td>
<td>The Role of Chinese Medicine in Integrative Cancer Therapies</td>
<td></td>
</tr>
<tr>
<td><strong>5:30 pm</strong></td>
<td>Chinese Medicine Knowledge and Experience Sharing</td>
<td></td>
</tr>
<tr>
<td><strong>6:00 pm</strong></td>
<td>Closing Ceremony</td>
<td></td>
</tr>
</tbody>
</table>
項目概述

在全球對食品及藥物安全要求不斷提升下，嚴謹及有系統的管理已成為整個“產品生命週期”的關鍵要素。由“產品”的設計、選料、生產製造、銷售都涉及這個管理理念，而藥品的 GMP 管理就是在生產過程中的其中一個把關點。實際上，不論是原料供應商、製造商、零售批發商乃至整個業界，都應知道這管理概念是如何運作。

每當提及中藥製造的 GMP 規範時，業界都會聯想成是“遙不可及、高不可攀的”或是“不可能勝任的”，甚至是業務難以繼續維持、生計不保的事情。無疑在建設 GMP 的品管系統時，需投入大量資源，而其中資金、地方及人員的配合更是重要的考慮，並需要周詳的計劃。

對製造商而言，彷如非傾囊而出去提升至 GMP 要求或結束業務不可。GMP 的設立不僅需要個別企業的付出，還需各方面的努力和配合，方可讓中藥產業得以持續發展。為使本港中藥業界對整體業務發展方向有更踏實的準備，香港生物科技研究院特別申辦“中藥製造之 GMP 基礎培訓暨資料搜集”項目，盼能藉此為協助業界的長遠發展。透過創新及科技基金的資助與業界的鼎力支持和贊助，為業界提供培訓課程。

是次免費項目為期 12 個月，以中藥行業的管理層為對象，課程包括 GMP 基礎培訓、廠房實地參觀及專家與製造商的個別面談。

(一) 兩天基礎 GMP 培訓 (2013 年 9 月至 2014 年 1 月中進行)

提供為期兩天的基礎 GMP 入門培訓，以每班四十人為標準，連續兩天由本院 GMP 專家 -— 楊樹英博士及劉耀珊女士擔任講解。內容包括：GMP 核心知識；產品選擇與劑型；廠房設計基礎及驗證要求。以小班形式為入門培訓，提供基礎 GMP 知識，並期盼透過講者及與會者之間的交流，讓參加者對未來業務發展有更清楚的方向。
(二)兩小時 GMP 廠房實地參觀及問卷收集（暫定於 2014 年 1 月至 3 月中進行）

完成兩天基礎 GMP 培訓後，本院將為參加者分組，以便參觀本院的 GMP 車間，GMP 專家將分析和解答有關的提問，讓參加者能更具體地了解 GMP 軟件及硬件的要求。屆時，本院更備問卷收集意見，以作日後課程設計的參考，及讓課程配合業界的發展。

(三)深人個別面談（暫定於 2014 年 4 月至 5 月中進行）

項目的最後一環是探討個別企業對 GMP 發展的意見。藉此交流平台，讓有需要的企業能與本院 GMP 專家作個別交流，使本院更深入了解本地中成藥製造商各自對執行 GMP 時所面對的各種考慮。透過是次活動，讓本院進一步了解業界對未來業務發展的期望及需要，冀望能在處理有關 GMP 的技術問題上有所幫助。有意者可於上述第二項活動時即場報名參加。

透過上述的三項活動，本院冀望能加深業界對 GMP 的認知及理解，更能從不同角度掌握未來業務的發展策略。

此項目歡迎中藥業界的管理代表參加。有意者可填妥報名表格，以傳真、郵遞或電郵方式寄回本院。本院職員將作回覆確認。

傳真：26035012
電郵：pcm-training@hkib.org.hk

如對上述項目有任何疑問，可致電 2948 9277 或以電郵方式與本院職員莊小姐或葉小姐聯繫。
中藥研發研討會
中西結合 提升競爭優勢

論壇反應熱烈

中藥研發議題是近年來的熱門話題。香港特首林鄭月娥指出，政府近年不斷推出措施，支持中藥業的發展。她表示，目前香港的中藥業發展仍需進一步完善，政府將會繼續努力，推動中藥業的發展。

中藥研發委員會

中藥研發委員會是政府為推動中藥業發展而設立的機構。委員會由多名來自中藥、藥學、生物科技、醫學等不同領域的專家組成。委員會的主要職能包括：

1. 推動中藥業的發展；
2. 提升中藥業的競爭力；
3. 推動中藥業的国际化；
4. 支持中藥業的研發和創新；
5. 推動中藥業的教育和培訓。

中藥研發委員會的主要任務是推動中藥業的發展。他們的工作包括：

1. 推動中藥業的研究和發展；
2. 推動中藥業的國際化；
3. 支持中藥業的創新和發展；
4. 推動中藥業的教育和培訓。

中藥研發委員會的工作目標是：

1. 推動中藥業的發展，使中藥業在全球範圍內取得競爭優勢；
2. 支持中藥業的創新和發展，使中藥業在全球範圍內取得競爭優勢；
3. 推動中藥業的教育和培訓，使中藥業在全球範圍內取得競爭優勢；
4. 推動中藥業的國際化，使中藥業在全球範圍內取得競爭優勢。

中藥研發委員會的主要成員包括：

1. 政府部門的代表；
2. 行業組織的代表；
3. 科研機構的代表；
4. 中藥業的企業代表。

中藥研發委員會的工作方式是：

1. 定期召開會議，討論中藥業的發展情況；
2. 組織相關專業的研討會，討論中藥業的發展問題；
3. 組織相關專業的研討會，討論中藥業的發展問題；
4. 組織相關專業的研討會，討論中藥業的發展問題。

中藥研發委員會的工作目標是：

1. 推動中藥業的發展，使中藥業在全球範圍內取得競爭優勢；
2. 支持中藥業的創新和發展，使中藥業在全球範圍內取得競爭優勢；
3. 推動中藥業的教育和培訓，使中藥業在全球範圍內取得競爭優勢；
4. 推動中藥業的國際化，使中藥業在全球範圍內取得競爭優勢。

中藥研發委員會的工作方式是：

1. 定期召開會議，討論中藥業的發展情況；
2. 組織相關專業的研討會，討論中藥業的發展問題；
3. 組織相關專業的研討會，討論中藥業的發展問題；
4. 組織相關專業的研討會，討論中藥業的發展問題。

中藥研發委員會的工作目標是：

1. 推動中藥業的發展，使中藥業在全球範圍內取得競爭優勢；
2. 支持中藥業的創新和發展，使中藥業在全球範圍內取得競爭優勢；
3. 推動中藥業的教育和培訓，使中藥業在全球範圍內取得競爭優勢；
4. 推動中藥業的國際化，使中藥業在全球範圍內取得競爭優勢。

中藥研發委員會的工作方式是：

1. 定期召開會議，討論中藥業的發展情況；
2. 組織相關專業的研討會，討論中藥業的發展問題；
3. 組織相關專業的研討會，討論中藥業的發展問題；
4. 組織相關專業的研討會，討論中藥業的發展問題。

中藥研發委員會的工作目標是：

1. 推動中藥業的發展，使中藥業在全球範圍內取得競爭優勢；
2. 支持中藥業的創新和發展，使中藥業在全球範圍內取得競爭優勢；
3. 推動中藥業的教育和培訓，使中藥業在全球範圍內取得競爭優勢；
4. 推動中藥業的國際化，使中藥業在全球範圍內取得競爭優勢。

中藥研發委員會的工作方式是：

1. 定期召開會議，討論中藥業的發展情況；
2. 組織相關專業的研討會，討論中藥業的發展問題；
3. 組織相關專業的研討會，討論中藥業的發展問題；
4. 組織相關專業的研討會，討論中藥業的發展問題。

中藥研發委員會的工作目標是：

1. 推動中藥業的發展，使中藥業在全球範圍內取得競爭優勢；
2. 支持中藥業的創新和發展，使中藥業在全球範圍內取得競爭優勢；
3. 推動中藥業的教育和培訓，使中藥業在全球範圍內取得競爭優勢；
4. 推動中藥業的國際化，使中藥業在全球範圍內取得競爭優勢。
中藥研發研討會 促進中醫藥發展

隨著中醫藥的規範制度漸趨健全，消費者對使用中醫服務及中藥的信心提升，中醫專業地位、中藥的安全性、質量及成效逐步確立。在此良好的基礎之上，今屆政府把推動本港中醫藥的發展列為重點工作之一，並積極檢視未來發展需要，讓普羅市民受惠。

自
從一九九九年訂定《中藥藥例》以來，政府亦從建立規範架構，確保本地中醫藥的質量，其中包括建立中醫師註冊制度等相關規定；繼而加強人才培訓，現時本地有三間大學已開設全日制中藥課程，為中醫藥界持續增添人材。

政府亦先後成立「中藥研究及發展委員會」及「中醫中藥發展委員會」，成員由多位來自中醫、中藥、藥學、科研、檢測和認證、醫療界別的代表及業內人士組成，旨在更有效地協調官、產、學、研各界，制定切合本港環境及需要的發展政策。

中醫中藥訂下的發展範疇

「中藥中藥發展委員會」由食物及衛生局局長高永文醫生擔任主席，他強調推動科研發展是發展中藥的重要元素，因此委員會主要研究範疇和探討的項目包括如何進一步推動中藥醫學的發展，加強中國中藥業及國際市場的關係，以及在東南亞國家的市場拓展。委員會亦會探討中藥業的發展前景及未來趨勢。

中醫中藥發展委員會

中藥發展委員會委員包括中藥業的代表及專家，以及東南亞國家的中藥業的代表。委員會的主要任務包括：

1. 推動中藥業的發展和推介
2. 推動中藥業的市場拓展
3. 推動中藥業的教育和培訓
4. 推動中藥業的科研和創新

加強人才培訓

另外三大範疇分別為「中藥業人才培訓及專業發展」、「中藥師服務」及「中藥產業發展」，就人才培訓方
面，高永文表示，「中藥業及相關科研工作要健康發展，人才培訓是其中一個重要支柱。為此，委員會會檢視現時中藥中藥的培訓課程，實踐及就業機會，以使有關培訓能切合業界的需求及需要。另一方面，我們明白業界對於發展中藥專科持有訴求，因此委員會亦會研究推動有關發展的可行性及方法。」

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資助創新研發 推動檢測認證

資料由客戶提供
政府一直重視香港的中醫藥發展，並於二〇一一年成立「中醫研究及發展委員會」，由創新科技署署長出任主席，目標是協調中醫藥界各持份者，共同推動中藥研發和檢測的工作。衛生署及醫院管理局的代表亦是該委員會的成員之一。中醫研究及發展委員會在香港醫療服務系統內是其中兩個關鍵機構，他們一方面保障市民健康和照顧市民的需要，另一方面積極推動本地及外地多個不同機構合作，使香港的中醫藥逐步走向現代化發展。

衛生署長陳漢儀博士在論壇開幕時指出，香港作為一個國際金融中心，有許多優勢可以推進中醫藥發展。他強調，香港的中醫藥發展應與國際標準接軌，並與國家的中醫藥發展戰略相結合。此外，香港還應積極推動中醫藥教育和培訓，以培養更多優秀的中醫藥人才。

“中醫藥發展走向現代化”這個論壇，旨在推動香港的中醫藥發展，並增進各界對中醫藥的認識。論壇將邀請多位專家就中藥研究、中醫教育、中藥製劑和中醫臨床應用等方面進行深入的探討和交流。論壇將於二〇二二年三月舉行，歡迎各界人士參加。

為中醫結合治療奠定基礎

論壇亦將就中醫藥在現代醫療中的應用進行探討。香港中醫藥總會會長黃國鴻表示，中醫藥與現代西醫藥的結合可以更有效地治療一些現代疾病。他指出，中醫藥在現代醫療中的應用正在逐步得到社會的認可和接受，相信未來中醫藥將在現代醫療中發揮更重要的作用。
研究創新
中西醫藥結合獲新優勢

香港是一個中西融合的國際大都會，一方面承傳中醫藥，另一方面掌握西方頂尖醫療技術。在中西醫研究及推廣中西醫結合方面，已具有獨特的優勢。香港多所大學亦積極投入，將中醫藥創新發展為推廣大業。

針灸治療受國際學界關注

中醫學在亞洲及世界數千年，對百病萬民而言，針灸治療已是一種不可或缺的療法。在內地及美國從中醫藥教學起步，於新加坡的香港大學中醫學院亦积极推进針灸治療的科研工作，推動中醫藥進駐海外。中西醫學家在研究過程中發現，針灸治療效果顯著，尤其是對慢性疼痛、失眠症、神經痛等疾病的治療。有研究顯示，針灸治療可以減緩疼痛、改善睡眠質素及減低心理壓力。

中藥研究項目國際領先

香港大學中醫藥學院由中藥研究項目國際化及創新，進行各類中藥研究項目，為藥物研發提供基礎。香港大學中藥學院年度研發預算達5000萬港元，其中一部分用於針灸治療的研究。項目圍繞中藥研究的機理，包括中藥的成分、作用機制及臨床應用等，進行深入研究。項目研究結果已於國際學術期刊上發表，其中一些研究已獲得國際學者的好評。

中醫藥質量研究

香港大學中醫藥學院一直注重中藥質量研究，進行各類中藥質量研究項目，為藥物研發提供基礎。項目圍繞中藥質量的機理，包括中藥的成分、作用機制及臨床應用等，進行深入研究。項目研究結果已於國際學術期刊上發表，其中一些研究已獲得國際學者的好評。

中藥研究質量

香港大學中藥學研究質量高，受到國際學者的好評。項目研究結果已於國際學術期刊上發表，其中一些研究已獲得國際學者的好評。

中藥研究質量

香港大學中藥學研究質量高，受到國際學者的好評。項目研究結果已於國際學術期刊上發表，其中一些研究已獲得國際學者的好評。